Expert Interview
A Look at Metsera's Phase I results for MET-097i and Phase II results for MET-097i in Obesity
Ticker(s): MTSR, PFEInstitution: University of Pittsburgh Medical Center
- Clinical Associate Professor of Medicine & Endocrinologist at UPMC
- Diabetes Clinical Unit Leader who sees 200+ patients with Type 1 Diabetes
- Clinical and Research Interest in diabetes technology and multidisciplinary modes of care
When reviewing the Phase I results for MET-097 and the Phase II results for MET-097i, what stands out most to you in terms of safety and early efficacy?
Added By: sara_adminIn your view, what unmet clinical needs could these agents address, and how might they fit alongside or compete with existing therapies?
Added By: sara_adminWhat further data would you need to see in later-phase studies before feeling confident about the potential role of MET-097 or MET-097i in your clinical practice?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
